The engineered human anti-tumor necrosis factor-α antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 26, Issue 11, 1999, Pages 2310-2317

  Choy, Ernest H S ^a   Rankin, Elizabeth C C ^b   Kassimos, Dimitri ^b   Vetterlein, Olivia ^b   Garyfallos, Alex ^b   Ravirajan, Chelliah T ^b   Sopwith, Mark ^b   Eastell, Richard ^b   Kingsley, Gabrielle H ^b   Isenberg, David A ^b   Panayi, Gabriel S ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Anti TNF ; Bone markers; Immunotherapy; Rheumatoid arthritis; Stromelysin; Tumor necrosis factor

Indexed keywords

CD4 ANTIGEN; DEOXYPYRIDINOLINE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PLACEBO; PYRIDINOLINE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHRITIS; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; URINALYSIS;

ANTIBODIES; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PEPTIDES; PHENOTYPE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032731245     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
2. Rankin EC, Choy EH. Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
3. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1β by monocytic cells: a possible role of CD69. European Cytokine Network 1993;4:15-23.
4. Brouckaert P, Libert C, Everaerdt B, Takahashi N, Cauwels A, Fiers W. Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology 1993;187:317-29.
5. Panagakos FS, Kumar S. Modulation of proteases and their inhibitors in immortal human osteoblast-like cells by tumor necrosis factor-alpha in vitro. Inflammation 1994;18:243-65.
6. Wolfe GC, MacNaul KL, Buechel FF, et al. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage. Quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis. Arthritis Rheum 1993;36:1540-7.
7. Sorsa T, Konttinen YT, Lindy O, et al. Collagenase in synovitis of rheumatoid arthritis. Semin Arthritis Rheum 1992;22:44-53.
8. Gruber HE. Bone and the immune system. Proc Soc Exp Biol Med 1991;197:219-25.
9. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-35.
10. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990;33:768-73.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Scott DL, Panayi GS, van Riel PL, Smolen J, van de Putte LBA. Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992;10:521-5.
13. Choy EHS, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992;36:291-8.
14. Colwell A, Russell RGG, Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993;23:341-9.
15. Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early postmenopausal woman by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994;9:135-42.
16. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-74.
17. Le Page SH, Williams W, Parkhouse D, et al. Relation between lymphocytotoxic antibodies, anti-DNA antibodies and a common anti-DNA antibody idiotype PR4 in patients with systemic lupus erythematosus, their relatives and spouses. Clin Exp Immunol 1989;77:314-8.
18. Ravirajan CT, Harmer I, McNally T, Hohmann A, Mackworth-Young CG, Isenberg DA. Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus. Ann Rheum Dis 1995;54:471-6.
19. Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis Int 1993;3:255-60.
20. Russell RG, Colwell A, Hannon RA, et al. Biochemical measurements in Paget's disease of bone. Semin Arthritis Rheum 1994;23:240-1.
21. Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14-7.
22. Palmela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol 1994;33:1012-6.
23. Chin JE, Winterrowd GE, Krzesicki RF, Sanders ME. Role of cytokines in inflammatory synovitis. The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts. Arthritis Rheum 1990;33:1776-86.
24. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule I. Arthritis Rheum 1994;37:992-9.
25. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumour necrosis factor a antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
26. Schriefer A, Barral A, Carvalho EM, Barral-Netto M. Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis. Clin Exp Immunol 1995;102:535-40.
27. Kurane I, Innis BL, Nimmannitya S. et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-γ in sera of children with dengue. J Clin Invest 1991;88:1473-80.
28. Ninova DI, Wiesner RH, Gores GJ, Harrison JM, Krom RA, Homburger HA. Soluble T lymphocyte markers in the diagnosis of cellular rejection and cytomegalovirus hepatitis in liver transplant recipients. J Hepatol 1994;21:1080-5.
29. Symons JA, Wood NC, Di Giovine FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-I and IL-2 inhibition. J Immunol 1988;141:2612-8.
30. Symons JA, McCulloch JF, Wood NC, Duff GW. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol 1991;60:72-82.
31. Moreland LW, Bucy RP, Weinblatt ME. Garrison L, Agosti JM. Effects of TNF-receptor (p75) fusion protein (TNFR:Fc; Enbrel) on immune function [abstract]. Arthritis Rheum 1998;41 Suppl:S59.
32. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
33. Samsom JN, Langermans JA, Savelkoul HF, van Furth R. Tumour necrosis factor, but not interferon-γ, is essential for acquired resistance to Listeria monocytogenes during a secondary infection in mice. Immunol 1995;86:256-62.
34. Elliott MJ, Maini RN. Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
35. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZBAV F1 mice. J Exp Med 1994;179:305-10.